
Overview
Background
MS has 35 years clinical research experience in pathogenesis and management of hypertension (HT), including endocrine varieties such as primary aldosteronism (PA). Working within the Greenslopes Hospital Hypertension Unit (GHHU), he helped demonstrate that PA is 10 times more common than previously thought and to account for approximately 10% of HT, making it the commonest specifically treatable, potentially curable variety, and in the description of a new familial form (FH-II) which recently led to the elucidation of its genetic basis (a gain of function mutation in CLCN2, published in Nature Genetics). The combined GHHU/Princess Alexandra Hospital HT Unit (PAHHU, which MS set up in 2000) has possibly the largest series (>2500) worldwide of patients with PA who have been thoroughly documented and meticulously studied, helping MS to become internationally recognized as an authority on pathogenesis/genetics, diagnostic workup and management of PA. In 2006, MS served as member of an international Task Force sponsored by the US Endocrine Society to develop the first guideline for diagnosis and management of PA (published in J Clin Endocrinol Metab and cited >1200 times with an update published in 2016 and cited >1900 times). He is currently Co-Chair of the working group for the third guideline. MS conceived, developed and validated the seated saline suppression test which has since become the favoured method for definitively confirming the diagnosis of PA in most Australian and in a rapidly growing number of overseas institutions. He has also made major contributions to the understanding of how various physiological and pharmacological factors affect the aldosterone/renin ratio as a screening test for PA and in optimizing approaches to adrenal venous sampling, the most reliable method of differentiating unilateral (surgically curable) from bilateral varieties.
Publications: MS has published 1 book, 20 textbook chapters and >250 papers in peer-reviewed scientific journals. His journal publications have been cited >14,000 times ("h" index 59).
Grant Support: Since 2019, MS has received ~$16 million in research grant support. He is currently a CI on two MRFF grants and an NHMRC CCRE.
Invited Presentations and Collaboration: MS has been invited to speak at major meetings 137 times (99 international) and has collaborated with researchers in >20 international Units and all Australian states. In 2018, was one of six investigators awarded a highly prestigious Leducq Foundation Transatlantic Networks of Excellence Program grant ($USD 6 million) to study the role of potassium in hypertension.
Committee Highlights: MS is past President of the Asian-Pacific Society of Hypertension and of the High Blood Pressure Research Council of Australia. During his time as HBPRCA President, initiatives that were introduced under his presidency included launching of a successful bid for 24h ABPM to be assigned an item number to enable a Medicare rebate of ABPM services. He was a Member of the NHF BP & Vascular Disease Advisory Committee 1998-2013.
Community Engagement: As President since 1995 of the Queensland Hypertension Association, a non-profit organization dedicated to promoting self-care in the management of hypertension, MS has overseen all of its activities, including bimonthly educational sessions and preparation of educational material for the general community and health professionals. On numerous occasions, MS has provided information to the community on issues related to hypertension by media interview.
Peer Review: Previously serving on Editorial Boards for of J Clin Endocrinol Metab, J Hypertens, Clin Exper Pharmacol Physiol, and Nephology, MS is currently Editor-in-Chief of J Hum Hypertens and a member of the Editorial Board for Hypertension. He has assessed 100’s of manuscripts for major international journals and served as grant application assessor on many occasions for major international and national funding bodies (including the NHMRC).
Other Awards and Honours: (1) John W.H. Tyrer Prize for Research in Internal Medicine, (2) Robert Vandongen Memorial Lecturer (University of WA), 2002, (3) Honorary Professor to the Xinjiang Institute of Hypertension, 2005, (4) Visiting Professor to the Tung Wah Eastern Hospital, Hong Kong, 2008, (5) Gaston Bauer Lecturer, Cardiac Society of Australia and New Zealand, 2012, (5) Nimmo Visitor, Royal Adelaide Hospital, 2015, (6) Paul Korner Award, Hypertension Australia, 2024.
Availability
- Professor Michael Stowasser is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor (Honours) of Medicine Surgery, The University of Queensland
- Doctor of Philosophy, The University of Queensland
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
Research interests
-
Determining the genetic basis for FH-II and other forms of primary aldosteronism
-
Improving methods of detection, diagnostic workup and management of primary aldosteronism
-
Validating a highly accurate method of measuring aldosterone using tandem mass spectrometry developed within the EHRC
-
Determining genetic factors which may modify phenotypic expression in FH-I, and thereby explain the wide spectrum of hypertens
-
Determining the extent to which aldosterone excess in humans is capable of causing cardiovascular and other organ dysfunction in
Research impacts
Hypertension (high blood pressure) affects around 30% of Australian adults, and is a leading risk factor for stroke. Treatment usually means lifelong medications, potentially costly and poorly tolerated. However, when the cause can be identified, and reversed or specifically treated, the outcomes are often dramatic with patients being able to come off many or all antihypertensives and enjoying markedly improved quality of life, while at the same time reducing their stroke risk.
The Endocrine Hypertension Research Centre (EHRC), a University of Queensland School of Medicine Centre based at Greenslopes and Princess Alexandra Hospitals, conducts internationally acclaimed research into the causes and management of various forms of hypertension, with a major focus on curable and specifically treatable varieties. It is the only Centre of its kind in Queensland and one of only a few internationally recognized Australian groups dedicated to hypertension-related clinical management and research. An important area of our work, for which the Centre has attracted much attention, has been our detailed studies into epidemiological, biochemical, morphological, pathophysiological and genetic aspects of a potentially curable form of hypertension known as primary aldosteronism (PA), in which the adrenal glands produce excessive amounts of salt retaining hormone (aldosterone). The EHRC demonstrated 20 years ago that PA is approximately ten times more common than previously thought, and accounts for as many as 10% of patients with hypertension. This finding has led to the identification of thousands of patients around the world who would otherwise have gone undetected, and in whom hypertension has been cured or markedly improved following surgical or specific medical treatment. More than 2000 thoroughly studied and documented patients with PA (probably the largest series worldwide) in our Centre provide a unique resource for further research into causes, diagnosis and treatment, and have led to important collaborations with first-class overseas investigators.
Research at the EHRC and elsewhere has shown that aldosterone excess in unrecognised PA is associated with significant cardiovascular morbidity which exceeds that due to hypertension alone. For example, the risk of stroke in PA is over four times higher than that for other forms of hypertension. In one rare familial form of PA, detectable by a genetic test developed in our Centre, hypertension can be particular severe and of early onset, leading to death at ages as young as 30 from hypertensive, haemorrhagic stroke. Because this increase risk is completely reversed by specifically treating the PA condition, it is vitally important that as many patients as possible with PA be identified among the hypertensive population. Major challenges exist in accurate diagnosis of PA, prompting our Centre to research better ways to achieve this, including through genetic testing and enhanced clinical and biochemical approaches, so that more people will be detected and given the opportunity to receive superior, highly effective treatment.
Among its many other projects, the Centre is actively involved in unlocking the genetic and molecular code of another form of hypertension known as Gordon syndrome (named after the Centre’s founder, Richard Gordon) which results in excessive retention of salt and potassium by the kidney. This work has the potentially to greatly enhance our understanding of how the kidney regulates salt balance and blood pressure, and to lead to the development of new drugs to treat hypertension and thereby prevent stroke.
Works
Search Professor Michael Stowasser’s works on UQ eSpace
2001
Conference Publication
Primary aldosteronism (PAL) at Princess Alexandra Hospital: Correcting Kaplan
Stowasser, M., Gunasekera, T. G., Cowley, D., Ward, G. and Smithers, B. M. (2001). Primary aldosteronism (PAL) at Princess Alexandra Hospital: Correcting Kaplan. 23rd Annual Scientific Meeting, Melbourne, 13-14 Dec 2001. Australia: High Blood Pressure Research Council of Aust Inc.
2001
Journal Article
Primary aldosteronism: Rare bird or common cause of secondary hypertension?
Stowasser, M. (2001). Primary aldosteronism: Rare bird or common cause of secondary hypertension?. Current Hypertension Reports, 3 (3), 230-239.
2000
Journal Article
Identifying Drug-Related Readmissions: Is There a Better Way of Assessing the Contribution of Adverse Medication Events?
Collins, D., Coombes, J., Staatz, C. E., Stowasser, D. and Stowasser, M. (2000). Identifying Drug-Related Readmissions: Is There a Better Way of Assessing the Contribution of Adverse Medication Events?. Australian Journal of Hospital Pharmacy, 30 (2), 47-52.
2000
Journal Article
Alpha-1-antitrypsin phenotypes in patients with renal arterial fibromuscular dysplasia
Bofinger, A., Hawley, C., Fisher, P., Daunt, N., Stowasser, M. and Gordon, Richard D. (2000). Alpha-1-antitrypsin phenotypes in patients with renal arterial fibromuscular dysplasia. Journal of Human Hypertension, 14 (2), 91-94.
2000
Journal Article
Alpha-1-antitrypsin phenotypes in patients with renal arterial fibromuscular dysplasia
Bofinger, A., Hawley, C., Fisher, P., Daunt, N., Stowasser, M. and Gordon, R. (2000). Alpha-1-antitrypsin phenotypes in patients with renal arterial fibromuscular dysplasia. Journal of Human Hypertension, 14 (2), 91-94. doi: 10.1038/sj.jhh.1000935
2000
Journal Article
Treatment of familial hyperaldosteronism type I: Only partial suppression of adrenocorticotropin required to correct hypertension
Stowasser, M., Bachmann, A. W., Huggard, P. R., Rossetti, T. R. and Gordon, R. D. (2000). Treatment of familial hyperaldosteronism type I: Only partial suppression of adrenocorticotropin required to correct hypertension. Journal of Clinical Endocrinology and Metabolism, 85 (9), 3313-3318. doi: 10.1210/jcem.85.9.6834
2000
Conference Publication
Clinical, biochemical and radiological overlap between familial hyperaldosteronism types I and II: Importance of genetic testing
Stowasser, M, Taylor, W, Daunt, N, Slater, G, Rossetti, T and Gordon, R (2000). Clinical, biochemical and radiological overlap between familial hyperaldosteronism types I and II: Importance of genetic testing. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2000
Journal Article
Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension
Stowasser, M, Bachmann, AW and Gordon, RD (2000). Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. The Journal of Clinical Endocrinology and Metabolism, 85 (9), 3313-3318. doi: 10.1210/jc.85.9.3313
2000
Journal Article
How common is adrenal-based mineralocortoid hypertension?
Stowasser, M. (2000). How common is adrenal-based mineralocortoid hypertension?. Current Opinion in Endocrinology & Diabetes, 7 (3), 143-150. doi: 10.1097/00060793-200006000-00007
2000
Conference Publication
Clinical, biomedical and radiological overlap between familial hyperaldosteronism type I and II: importance of genetic testing
Stowasser, M., Taylor, W., Daunt, N., Slater, G., Rossetti, T. and Gordon, R. D. (2000). Clinical, biomedical and radiological overlap between familial hyperaldosteronism type I and II: importance of genetic testing. Abstracts of the 18th Scientific Meeting of the Int. Society of Hypertension, Chicago, USA, 20-24 Aug 2000. Philadelphia, USA: Lippincott Williams & Wilkins.
2000
Conference Publication
Angiotensin II (AngII) receptors in AngII-responsive (AngII-R) and angII-unresponsive (AngII-U) aldosterone-producing adenoma (APA)
Stowasser, M, Zhuo, J, Ohishi, M, Mendelsohn, F and Gordon, R (2000). Angiotensin II (AngII) receptors in AngII-responsive (AngII-R) and angII-unresponsive (AngII-U) aldosterone-producing adenoma (APA). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2000
Journal Article
Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p
Benn, DE, Dwight, T, Richardson, AL, Delbridge, L, Bambach, CP, Stowasser, M, Gordon, RD, Marsh, DJ and Robinson, BG (2000). Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Research, 60 (24), 7048-7051.
2000
Journal Article
Severity of hypertension in familial hyperaldosteronism type I: Relationship to gender and degree of biochemical disturbance
Stowasser, M., Bachmann, A. W., Huggard, P. R., Rossetti, T. R. and Gordon, R. D. (2000). Severity of hypertension in familial hyperaldosteronism type I: Relationship to gender and degree of biochemical disturbance. The Journal of Clinical Endocrinology and Metabolism, 85 (6), 2160-2166. doi: 10.1210/jc.85.6.2160
2000
Journal Article
Primary aldosteronism: learning from the study of familial varieties
Stowasser, M and Gordon, RD (2000). Primary aldosteronism: learning from the study of familial varieties. Journal of Hypertension, 18 (9), 1165-1176. doi: 10.1097/00004872-200018090-00002
2000
Journal Article
A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22)
Lafferty, Antony R., Torpy, David J., Stowasser, Michael, Taymans, Susan E., Lin, Jing Ping, Huggard, Philip, Gordon, Richard D. and Stratakis, Constantine A. (2000). A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). Journal of Medical Genetics, 37 (11), 831-835. doi: 10.1136/jmg.37.11.831
2000
Journal Article
Identifying Drug-Related Readmissions: Is There a Better Way of Assessing the Contribution of Adverse Medication Events?
Stowasser, Danielle A., Staatz, Christine E., Stowasser, Michael, Coombes, Judith A. and Collins, David M. (2000). Identifying Drug-Related Readmissions: Is There a Better Way of Assessing the Contribution of Adverse Medication Events?. Australian Journal of Hospital Pharmacy, 30 (2), 47-53. doi: 10.1002/jppr200030247
2000
Conference Publication
Angiotensin II (Angll) receptors in angll-response (Angll-R) and angll-unresponsive (Angll-U) aldosterone-producing adenoma (APA)
Stowasser, M., Zhuo, J., Ohishi, M., Mendelsohn, F. and Gordon, R. D. (2000). Angiotensin II (Angll) receptors in angll-response (Angll-R) and angll-unresponsive (Angll-U) aldosterone-producing adenoma (APA). 18th Scientific Meeting of the Int. Society of Hypertension, Chicago, USA, 20-24 Aug 2000. Philadelphia, USA: Lippincott Williams & Wilkins.
1999
Journal Article
Increased severity of multifocal renal arterial fibromuscular dysplasia in smokers
Bofinger, A. M., Hawley, C. M., Fisher, P. M., Daunt, N., Stowasser, M. and Gordon, Richard D. (1999). Increased severity of multifocal renal arterial fibromuscular dysplasia in smokers. Journal of Human Hypertension, 13 (8), 517-520.
1999
Journal Article
Expression of 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma
Coulter, Catherine L., Smith, Robin E., Stowasser, Michael, Sasano, Hironobu, Krozowski, Zygmunt S. and Gordon, Richard D. (1999). Expression of 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. Mollecular and Cellular endocrinology, 154 (1-2), 71-77. doi: 10.1016/S0303-7207(99)00077-5
1999
Journal Article
Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I
Stowasser, M, Huggard, PR, Rossetti, TR, Bachmann, AW and Gordon, RD (1999). Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. Journal of Clinical Endocrinology and Metabolism, 84 (11), 4031-4036. doi: 10.1210/jc.84.11.4031
Funding
Current funding
Past funding
Supervision
Availability
- Professor Michael Stowasser is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Defining The Role Of Mineralocorticoid Receptor In Cardiometabolic Health & Inflammation & Optimising The Diagnostic Approach For Aldosterone-producing Adenoma
Principal Advisor
Other advisors: Dr Moe Thuzar
-
Doctor Philosophy
Defining The Role Of Mineralocorticoid Receptor In Cardiometabolic Health & Inflammation & Optimising The Diagnostic Approach For Aldosterone-producing Adenoma
Principal Advisor
Other advisors: Dr Moe Thuzar
Completed supervision
-
2022
Doctor Philosophy
Regulation of sodium chloride cotransporter (NCC) in health and disease
Principal Advisor
-
2020
Doctor Philosophy
Histopathological, Biochemical and Genetic Characterization of Different Types of Primary Aldosteronism, Including Validation of a New Angiotensin Assay
Principal Advisor
-
2017
Doctor Philosophy
Clinical and Physiological Aspects of Salt Sensitive Hypertension
Principal Advisor
-
2012
Doctor Philosophy
The interplay of salt and aldosterone in determining ill-effects of aldosterone excess in the cardiovascular and renal system and stimulating salt appetite
Principal Advisor
-
2011
Doctor Philosophy
Primary Aldosteronism-Pharmacological and Physiological Factors influencing diagnosis and management.
Principal Advisor
-
2009
Doctor Philosophy
Genetic, Diagnostic and Therapeutic Aspects of Primary Aldosteronism
Principal Advisor
-
Doctor Philosophy
GENETICS OF PRIMARY ALDOSTERONISM - FAMILIAL HYPERALDOSTERONISM TYPE II
Principal Advisor
-
2003
Doctor Philosophy
Fibromuscular dysplasia of the renal arteries: Studies on aetiology
Associate Advisor
Media
Enquiries
Contact Professor Michael Stowasser directly for media enquiries about:
- Aldosteronism - primary
- Cardiac irregularities
- High blood pressure
- Hyperaldosteronism
- Hypertension
- Hypertension - familial forms
- Pathophysiology
- Phaeochromolytoma
- Renal artery sterosis
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: